Pediatric Hematology/Oncology

BRAF+

Questions discussed in this category

Do you recommend using BRAFV600E mutation status to risk stratify treatment for a pediatric patient with langerhans cell histiocytosis?

1 Answer available

Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?

0 Answers available

Papers discussed in this category

J. Pediatr., 2014 Oct 21

Differentiating skin-limited and multisystem Langerhans cell histiocytosis.

Related Topics in Pediatric Hematology/Oncology